

# Reference Laboratories Can Make Validation More Efficient

Erin H. Hill<sup>1</sup>, Hans A. Raabe<sup>1</sup>, and Rodger D. Curren<sup>1</sup>


Institute for In Vitro Sciences, Inc., Gaithersburg, MD, USA

## Abstract

The validation of *in vitro* methods is a lengthy process encompassing multiple phases. It progresses from initial test development, through test optimization and prevalidation, to a formal validation assessment, and eventually to regulatory acceptance. Each of these phases relies heavily on the outcome of laboratory activities - even the regulatory acceptance step involves careful inspection of the data to determine their applicability to the regulatory need under consideration. The competence and experience of laboratories participating in each phase have a significant effect on the efficiency of the entire process. History has shown that the process is never as fast as we would like; however, it can be even slower if technical errors are made along the way. High-quality laboratory work is required to maximize the opportunity for success at each stage. This emphasizes the need for a group of experienced, competent laboratories (reference laboratories) capable of readily participating in any of the phases. Such laboratories should be able to conduct assays under GLP-compliant conditions, and should optimally be independent from the developers. Reference laboratories experienced in each of the phases are particularly valuable to the process since they will be able to help test developers at an early stage to design robust protocols that can withstand the rigors of validation and subsequent routine usage. They will also be able to support the successful implementation of assays to naive laboratories post-validation, and assist the regulatory agencies in training reviewers to correctly interpret data from newly approved *in vitro* assays.

## Desired Attributes of a Reference Laboratory

- Independence from assay developers and manufacturers
- GLP-compliant
- Experience in the following:
  - Routine use of *in vitro* assays
  - Scientific and regulatory needs of industry
  - Requirements of regulatory agencies
  - Working under validation study conditions



## Conclusions

An increasing number of alternative methods need to be assessed to meet the growing legislative and scientific demands. In order to evaluate these methods in a timely manner, the validation and acceptance process must be as efficient as possible. Often progression through the validation process is unnecessarily delayed by method developers lacking information on regulatory requirements and exact industry needs, and subsequently by time spent in identifying testing laboratories that have the ability to execute validation programs without significant additional preparation and training. Importantly, final industry adoption of approved methods can be slowed by lack of experience and training.

One way to increase efficiency is to utilize a set of well qualified, experienced reference laboratories to assist numerous stakeholders, including method developers, industry scientists, validation authorities and regulatory agencies. These laboratories should be GLP-compliant and have trained staff that perform a variety of *in vitro* tests on a regular basis. This expertise could be quickly applied to any stage of the validation and acceptance process, and would significantly decrease the time elapsed between the first test prototype and routine industry use of a regulatory accepted method. The benefits of such a set of reference laboratories are clear - a way to provide financial support and thus ensure the existence of such laboratories should now be investigated.

## One Way Forward

Finding an organization that meets all the desired attributes of a reference laboratory is very difficult. The technical staff must maintain a high quality level of training and proficiency in a wide variety of *in vitro* techniques. This generally occurs only in a laboratory that regularly conducts a wide range of *in vitro* assays. One potential candidate is a GLP-compliant contract research organization (CRO) that offers a diverse set of alternative methods. A CRO has the added benefit of understanding the needs of industry and the potential industrial uses for a new method.

However, one substantial obstacle for a CRO in considering the Reference Laboratory concept is the balance between the demands of commercial work and that of validation projects. Validation contracts rarely cover the full costs of the project and industry's commercial needs can often take priority. To overcome this obstacle some type of supplemental funding and a strong corporate commitment to alternatives is necessary.